Anti-Coagulants - Lesotho

Lesotho

In Lesotho, the revenue in the Anti-Coagulants market is projected to reach US$0.64m in 2024.
This market is expected to show an annual growth rate (CAGR 2024-2029) of 7.53%, resulting in a market volume of US$0.92m by 2029.
When compared globally, it is worth noting that United States will generate the most revenue in this market, with an estimated US$16,740.00m in 2024.
Despite the high prevalence of cardiovascular diseases in Lesotho, the use of anti-coagulants remains limited due to lack of access to healthcare facilities and affordability constraints.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Lesotho has been developing at a steady pace in recent years.

Customer preferences: Patients in Lesotho who suffer from blood clots or other conditions that require anti-coagulants prefer drugs that are affordable and effective. They also prefer drugs that have minimal side effects and can be easily acquired from local pharmacies.

Trends in the market: One trend that has been observed in the Anti-Coagulants market in Lesotho is the increasing availability of generic drugs. This has been driven by the expiration of patents on several branded drugs. As a result, patients are able to access more affordable drugs that are just as effective as the branded ones. Another trend is the increasing use of direct oral anticoagulants (DOACs) as opposed to traditional anti-coagulants such as warfarin. DOACs are preferred by patients as they require less monitoring and have fewer drug interactions.

Local special circumstances: Lesotho is a small country with a population of just over 2 million people. The country has a high prevalence of HIV/AIDS, which increases the risk of blood clots. In addition, the country has a high burden of tuberculosis, which can also increase the risk of blood clots. These factors have contributed to the growing demand for anti-coagulants in Lesotho.

Underlying macroeconomic factors: The Lesotho government has been investing in the healthcare sector in recent years, with a focus on improving access to healthcare for all citizens. This has led to an increase in the availability of healthcare facilities and medicines, including anti-coagulants. In addition, Lesotho is a member of the Southern African Customs Union (SACU), which has facilitated trade in pharmaceutical products between member countries. This has made it easier for pharmaceutical companies to import and distribute their products in Lesotho.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.